Brain mapping’s path to developing cure for Alzheimer’s

Latest articles

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Longevity Science Summit: care of aging population talks continue

Our dive into Longevity Week's Science Summit continues... Last week, Longevity.Technology was lucky enough to attend Longevity Forum's Science Summit at Oxford's Oriel College, part...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Click the globe for translations.

Alzheimer’s is a devastating neurodegenerative disease – now a new brain mapping technique might allow scientists to understand exactly how it progresses through the brain and enable individualised patient predictions.

Scientists mapping the progression of dementia in the brain have been trying to understand how it spreads – does the atrophy associated with Alzheimer’s and other forms of progressive dementia spread out from an original source, or does it use synaptic pathways in the brain to travel to other locations and set up additional fronts of attack. After all, the received wisdom that Alzheimer’s was caused by clumps of amyloid plaques is already being questioned.

A new study by the University of California San Francisco set out to tackle this question by mapping frontotemporal dementia (FTD), a condition in which the frontal and temporal anterior lobes of the brain atrophy. This causes two types of symptoms: behavioural changes and language problems.

Longevity.Technology: FTD cannot be slowed, stopped or cured and is the most common form of dementia in people under 60 [1]. This research provides an insight into how the disease spreads and how its progression varies from patient to patient. This variability has been an obstacle to successful clinical trials, so by successfully mapping the disease’s progression, the journey to therapy has begun and will allow treatments to be developed, invested in and brought to market.

The TRL score for this Longevity.Technology domain is currently set at:

The TRL score for the technology addressed in this article is: “Early proof of concept demonstrated in the laboratory.”

As lead author Dr Jesse Brown, commented: “Knowing how dementia spreads opens a window onto the biological mechanisms of the disease — what parts of our cells or neural circuits are most vulnerable. You can’t really design a treatment until you know what you’re treating [2].”

The study, the results of which were published in Neuron earlier this week, involved a group of 42 people who suffered from one of two subtypes of FTD having an MRI scan at the beginning of the study and another one about 12 months later. The researchers analysed the data to map the disease’s progression by comparing it with MRI brain scans of 75 healthy participants. The research team were able to create standardised maps of 175 different brain areas and the corresponding regions with which they communicated, working out the “patient-tailored epicentre” of brain degeneration and how the atrophy would spread. They found that the results supported the hypothesis that neurodegenerative diseases don’t spread evenly in all directions like a tumour; rather they leap from one part of the brain to another along the neuro-highways in the brain.

“It’s like with an infectious disease, where your chances of becoming infected can be predicted by how many degrees of separation you have from ‘Patient Zero’ but also by how many people in your immediate social network are already sick,” says Dr Brown [3].

He added: “Just like epidemiologists rely on models of how infectious diseases spread to develop interventions targeted to key hubs or choke points, neurologists need to understand the underlying biological mechanisms of neurodegeneration to develop ways of slowing or halting the spread of the disease.”

Co-author Dr William Seeley said: “We are excited about this result because it represents an important first step toward a more precision medicine type of approach to predicting progression and measuring treatment effects in neurodegenerative disease.”

Although the Alzheimer’s mapping method and associated predictions are not yet ready for clinical trial, the researchers hope that it will lead to improved metrics for evaluating therapies already entering clinical trials. Is there a potential crossover with Elon Musk’s Neuralink, with technology using the brain’s neural superhighways to beat disease and degeneration and bring us closer to Longevity? Fire up the satnav – exciting times are ahead!

[1] https://www.theaftd.org/what-is-ftd/disease-overview/
[2] https://www.sciencedaily.com/releases/2019/10/191014111730.htm
[3] https://www.medicalnewstoday.com/articles/326689.php

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

Klotho: The protein that could extend your healthspan and lifespan

The protein Klotho is big longevity news – but how can you measure it, and how can you improve your levels? KlothoBios is a...

A global perspective on consumer longevity data

WHO head of aging and health to present at ARK event focused on the importance of data in the quest for improved longevity. Tomorrow is...

A gathering of the longevity clans

Longevity Biotech Association: Launch of new non-profit heralds a more unified approach across the longevity industry spectrum. Leaders from across the longevity sector came together...

    Subscribe to our newsletter